Neurent Medical announced that its PARAGON study demonstrated durable two-year efficacy and safety of the NEUROMARK® System, with patients experiencing significant and sustained improvements in chronic rhinitis symptoms and quality of life. Results, published in Ear, Nose, & Throat Journal, confirm NEUROMARK’s transformative potential for both allergic and nonallergic rhinitis patients.
We’re proud to share that Cigna Healthcare has officially removed CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective September 15, 2025.
Neurent Medical has received FDA 510(k) clearance for its next-generation NEUROMARK® System, a minimally invasive device that provides ENT specialists with enhanced control, real-time feedback, and treatment confirmation for chronic rhinitis. Developed in collaboration with leading ENT experts, the updated system is now positioned for broader U.S. availability to meet growing demand.
3-month results from the CLARITY Study Show the NEUROMARK® System provides safe and effective treatment for patients with Chronic Rhinitis.
Explore 12-month safety and efficacy outcomes for treating Chronic Rhinitis with NEUROMARK®.
PARAGON 6-month Study data shows NEUROMARK® treatment benefits allergic and nonallergic rhinitis patients.
